

Is the Juice Worth the Squeeze? Overall Survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers.

Nuradh Joseph^{1,2}

Vodathi Bamunuarachchi^{2,3}

Vimukthini Peiris^{2,4}

Sidath Wijesera^{2,5}

Daminda Rajapakse^{2,6}

Sanjeeva Gunasekera^{2,3}

1. District General Hospital, Hambantota, Sri Lanka.
2. Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.
3. Apeksha Hospital, Maharagama, Sri Lanka
4. District General Hospital, Vavuniya, Sri Lanka.
5. District General Hospital, Avissawella, Sri Lanka.
6. Teaching Hospital, Ratnapura, Sri Lanka.

Keywords: cost-effectiveness, oncology, clinical benefit, overall survival, treatment duration

Funding: This work did not receive any specific funding from any governmental, private or not-for-profit organization.

Conflicts of Interest: None declared

Corresponding Author:

Dr. Nuradh Joseph MD MRCP FRCR
Consultant Clinical Oncologist,
District General Hospital, Hambantota,
Hambantota, Sri Lanka
Tel: +94777745544
Email: m23355@pgim.cmb.ac.lk

Abstract

Introduction

Novel systemic therapeutic options such as enzyme inhibitors and monoclonal antibodies have transformed the practice of medical oncology in the recent past. However, survival gains remain modest in most cases. Quantifying the magnitude of benefit against financial and non-financial toxicity of treatment is pivotal in deciding treatment. We describe a novel metric which can be used to assess effectiveness novel therapeutics for incurable cancers.

Methods

The median overall survival was divided by the median duration of treatment to obtain the overall survival gain per treatment time which was the primary end-point of the study. This parameter was compared with the European Society of Medical Oncology Magnitude of clinical benefit scale (ESMO-MCBS) score. Spearman's rank correlation coefficient was used to test the association between the novel metric and the ESMO-MCBS scores.

Results

Data were available for 30 drugs across 60 indications. The median overall survival per unit treatment time ranged from 0.68 (range 0.2-0.51). Only 18/60 indications had a ratio greater than 1 while 13/60 indications had a ratio less than 0.5. The median treatment duration was not mentioned in 11 indications and median progression free survival was substituted for the analysis. The ESMO-MCBS score was available for 49 of the indications. The Spearman's rank correlation coefficient was 0.44575 and showed a statistically significant association between survival gain per unit treatment time and the ESMO-MCBS score ($p = 0.00133$).

Conclusions

Along with other metrics, the ratio of survival gain over treatment duration is a useful parameter to assess effectiveness of novel therapeutics in the palliative setting.

Introduction

Although cure rates have improved significantly over the last couple of decades, nearly 50% of all cancers are still incurable (1). For patients with incurable cancer, the objective of treatment is to prolong survival while improving or maintaining quality of life. A large number of novel cancer therapeutic agents ranging from complex monoclonal antibodies to small molecule enzyme inhibitors and new types of hormonal treatment, have been approved for use in incurable cancers and while this has led to modest improvements in survival it comes at the price of significant toxicity as well as a heavy financial burden on health systems (2).

Oncologists prescribe systemic treatment in incurable cancer with a view to shrinking the tumour and/or preventing its growth but eventually the cancer develops resistance and progresses through treatment. The outcome end-points response rate, duration of response and progression free survival capture these aspects of treatment. However, they are not a robust surrogate marker for the overall survival which is considered as the primary end-point of choice (3,4).

Systemic treatment of incurable cancers is continued until tumour progression, which is defined as an increase in the sum of maximum tumour diameters of at least 20%, the development of any new lesions, or an unequivocal increase in non-measurable malignant disease, in comparison to the preceding assessment. Intolerable toxicity is another factor which could lead to a premature termination of treatment (5). The duration of treatment is an important metric that ought to be reported in all publications of trials involving novel cancer agents (6). It is the primary determinant of the direct cost of treatment and the time of exposure to treatment will impact on treatment toxicities.

In this work, we explore the novel metric overall survival gain per unit treatment time as a useful parameter to supplement other established measures of clinical benefit such the European Society of Medical Oncology - Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the American Society of Clinical Oncology (ASCO) Value Framework score (7,8).

Methods

Data on median overall survival gain and median duration of treatment were obtained from publications of phase III randomised clinical trials for novel anti-cancer therapeutics in the palliative setting.

In trials with significant treatment cross-over estimates of median survival gain were substituted where such data was available. Studies were excluded if no overall survival gain was demonstrated and where there were no published studies of estimates of overall survival gain.

Trials in which median overall survival was not reached were also excluded from the analysis. If the median duration of treatment was not reported the median time to progression was substituted for it.

The median overall survival was divided by the median duration of treatment to obtain the overall survival gain per treatment time which was the primary end-point of the study. This parameter was compared with the ESMO-MCBS score. Spearman's rank correlation coefficient was used to test the association between the novel metric and the ESMO-MCBS scores. The statistical Software R version 4.1.1 was used for analysis

Results

Data were available for 30 drugs across 60 indications. Supplementary table S1 gives the full dataset of the analysis including the referenced publications from which data was extracted. Table 1 presents the values of the metric for 40 selected indications. The median overall survival was 5.8 months (range 1.4 - 42.2 months) and the median treatment duration was 8 months (range, 1.9-78 months). The median overall survival per unit treatment time ranged from 0.68 (range 0.2-0.51). Supplementary Figure S1 depicts in the form of a histogram the number of indications for each survival gain per unit treatment time. Since the distribution was skewed a logarithmic transformation was performed to achieve greater normality, and the histogram of the logarithm of the metric is presented in Figure 1. The median of the logarithm of the survival gain per unit treatment time was -0.17 (range -0.71-0.7).

Only 18/60 indications had a ratio greater than 1 while 13/60 indications had a ratio less than 0.5. The median treatment duration was not mentioned in 11 indications and median progression free survival was substituted for the analysis. The ESMO-MCBS score was available for 49 of the indications. The Spearman's rank correlation coefficient was 0.44575 and showed a statistically significant association between survival gain per unit treatment time and the ESMO-MCBS score ($p = 0.00133$).

Discussion

In this work, we present a novel metric, survival gain per unit treatment time, as a useful parameter that could complement other measures of clinical benefit such as the ESMO-MCBS score. Ideally clinicians would want the benefit of treatment to outlast its duration, leaving a prolonged therapeutic legacy of benefit to the patient. This can be achieved if the novel drugs result in significant tumour shrinkage which is sustained for a prolonged time period. Treatments with a survival gain per treatment time > 1 would fall into this category, and are likely to be preferred by patients since the gain in survival is greater than exposure to the drug and its toxicity. In addition, they are likely to be more cost-effective since the cost of treatment is related

to drug exposure time. A value of less than 0.5 with our novel metric, would indicate that patients need to be exposed to the treatment for almost twice the duration of survival gain, and these are likely to pose a heavy burden in terms of toxicity, both financial and non-financial for modest benefit.

A significant proportion of patients are not fit for second line treatment at the time of disease progression and there is a trend to use the most efficacious agents earlier in the course of the disease trajectory of metastatic cancer with a view to improving survival. The rationale for this approach is firmly rooted in the proportional hazards model, where for the same relative reduction of risk of death a higher absolute gain can be achieved if treatment is initiated early.

It was interesting to note that when considering first-line versus later line of treatment in the same disease for the same agent, it could be discerned that the survival gain per treatment time is higher when used in later lines of treatments for most drugs. Since treatment duration is often longer when used in the first line setting, it follows that the cost of treatment would also be greater in comparison to use of the same agent in the second line. The lower survival gain per treatment time in first line use would suggest that more robust biomarkers are needed to distinguish patients who would benefit from first line treatment from those who are suitable for sequential treatment. A notable exception to this trend was observed with the use of abiraterone in hormone sensitive metastatic prostate cancer where the survival gain per treatment time was greater in this setting than in the castration resistant phases of the disease.

Our metric places a higher premium on indications for which there are existing treatment options, since the novel agent has to achieve a survival gain relative to its treatment duration. We believe that this is a strength of the metric since it helps select treatments which are robustly effective from those which achieve only modest gains.

Since its publication the ESMO-MCBS has found widespread application as a robust tool of stratifying the benefit of each novel agent since it weaves together improvements in prolongation of survival while considering toxicity and quality of life into a single parameter. In the palliative setting the ESMO-MCBS classifies reported outcomes into five levels 1-5 with higher values indicating a higher clinical benefit. For trials reporting improvements in overall survival, the ESMO-MCBS scoring is based upon a consideration of the absolute gain in median overall survival, the lower limit of the confidence interval of the hazard ratio as well as reported gains in quality of life as well reduced grade 3 or 4 toxicity in comparison to the control arm.

It has been shown that although the cost of novel cancer drugs has increased over the past decade, clinical benefits did not follow a similar trend (9). Although there was a statistically significant association between our metric and the ESMO-MCBS score. The highest values for the novel metric was seen with the use of the PD-1 inhibitors nivolumab and pembrolizumab in

metastatic melanoma, for which the ESMO-MBCS score was 4. However, while ribociclib in premenopausal metastatic breast cancer had a maximum value of 5 within the ESMO-MBCS scoring, it had a low value of 0.45 with our metric. Sunitinib in the second line treatment of unresectable gastrointestinal stromal tumours had a high value of 2.67 in our study but had an ESMO-MBCS score of just 3.

Unlike the ESMO-MBCS which is reported as a score of an ordinal scale, our metric is a continuous variable. Reporting the survival gain per treatment duration along with the conventional end-points such as response rates, median overall survival and the ESMO-MBCS would enable clinicians and patients to make more informed therapeutic decisions especially when weighing the benefit against toxicity.

It needs to be emphasised that the median duration of treatment was not disclosed in 11/60 studies that were screened. As mentioned previously, treatment duration is pivotal in deciding the cost of treatment which is an integral component of all cost-effectiveness and health technology modelling studies, and its reporting needs to be made mandatory in publications of phase III randomised trials.

There are a number of limitations in our study and in our novel metric. First, we excluded studies in which no overall survival gain was established. In many trials, when the primary end-point of a gain in progression-free survival is met crossover is permitted, adding to the complexity of determining the impact of the novel drug on overall survival (10,11). It would also mean that treatments that achieve improvements in quality of life without prolonging survival were also not considered in this analysis (12). Second, we used median progression-free survival as a surrogate in studies which did not report the median duration of treatment. As mentioned before, treatment in the non-curative setting is continued until disease progression or development of treatment toxicity and as such, progression free survival would therefore be longer than the duration of treatment in most instances. This may have led to underestimation of the survival gain per unit treatment time for certain indications.

Conclusion

Overall survival gain per unit treatment duration is a potentially useful metric that would provide vital insights in quantifying the benefit of treatment of novel cancer therapeutics in the palliative setting. The juice in the form of survival gain must certainly do justice to the squeeze both in terms of financial and somatic toxicities.

References

1. Cancer Research UK Available at: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/survival/all-cancers-combined> (Accessed 15th February 2023).
2. Latino NJ, Galotti M, Cherny NI, de Vries EGE, Douillard JY, Kaidarova D, Ilbawi A. Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience. *ESMO Open*. 2022 Feb;7(1):100362. doi: 10.1016/j.esmoop.2021.100362.
3. Gyawali B, Eisenhauer E, Tregear M, Booth CM. Progression-free survival: it is time for a new name. *Lancet Oncol*. 2022 Mar;23(3):328-330. doi: 10.1016/S1470-2045(22)00015-8.
4. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? *J Clin Oncol*. 2012 Apr 1;30(10):1030-3. doi: 10.1200/JCO.2011.38.7571.
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
6. Haslam A, Olivier T, Thawani R, Prasad V. Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm? *ESMO Open*. 2022 Jun;7(3):100480. doi: 10.1016/j.esmoop.2022.100480.
7. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. *J Clin Oncol*. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518.
8. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. ESMO-Magnitude of Clinical Benefit Scale version 1.1. *Ann Oncol*. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.

9. Saluja R, Arciero VS, Cheng S, McDonald E, Wong WWL, Cheung MC, Chan KKW. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. *J Oncol Pract*. 2018 May;14(5):e280-e294. doi: 10.1200/JOP.17.00058.
10. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. *J Clin Oncol*. 2008 Mar 10;26(8):1371-8. doi: 10.1200/JCO.2007.13.5335.
11. Jönsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, Jönsson B, Weinstein MC, Drummond M. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. *Value Health*. 2014 Sep;17(6):707-13. doi: 10.1016/j.jval.2014.06.006
12. Zhang B, Nilsson ME, Prigerson HG. Factors important to patients' quality of life at the end of life. *Arch Intern Med*. 2012 Aug 13;172(15):1133-42. doi: 10.1001/archinternmed.2012.2364.

List of Tables and Figures

Table 1 Overall survival gain per unit treatment time (selected indications)

Figure 1 Distribution of indications against logarithm of survival gain per unit treatment time

Supplementary Table 1 Overall survival gain per unit treatment time (Full Dataset)

Supplementary Figure S1 Distribution of indications against survival gain per unit treatment time

Table 1

Overall survival gain per unit treatment time (selected indications)

Drug	Indication	Median Survival gain (In months)	Median Treatment Duration (In months)	Overall Survival gain per unit treatment time	ESMO-MCBS Score
Abiraterone	Metastatic Hormone Sensitive Prostate Cancer	16.8	25.80	0.65	4
Abiraterone	Metastatic Castration Resistant Prostate Cancer Post Docetaxel	3.9	8.00	0.49	4
Abiraterone	Metastatic Castration Resistant Prostate Cancer Pre Docetaxel	4.4	13.77	0.32	4
Bevacizumab	Platinum Refractory Epithelial Ovarian Cancer	3.3	4.20	0.79	4
Bevacizumab	Metastatic Cervical Cancer	3.7	4.90	0.76	3
Bevacizumab	Metastatic Colorectal Cancer 2nd line	2.1	4.67	0.45	3
Bevacizumab	Platinum Sensitive Relapsed Epithelial Ovarian Cancer	4.9	11.20	0.44	3
Bevacizumab	Metastatic Epithelial Ovary Cancer 1st line	4.8	11.90	0.40	3
Cetuximab	Unresectable Squamous cell carcinoma of Head and Neck 1st Line treatment in combination with chemotherapy	2.7	4.20	0.64	3
Cetuximab	Metastatic RAS wildtype left sided colorectal cancer 1st line treatment in combination with chemotherapy	7	12.00	0.58	4
Cetuximab	Treatment Refractory RAS wildtype Metastatic Colorectal Cancer (as monotherapy)	4.7	3.70	1.27	4
Fulvestrant	Metastatic Hormone Sensitive Breast Cancer 1st Line	7.8	15.00	0.52	2

Fulvestrant	Metastatic Hormone Sensitive Breast Cancer 2nd Line	4.1	6.50	0.63	Not Assessed
Lenvatinib	Radioiodine Refractory Metastatic Differentiated Thyroid Cancer	11.6	23.00	0.50	2
Nab-Paclitaxel	Advanced Pancreatic Cancer	2.6	3.90	0.67	3
Nivolumab	Metastatic Melanoma	26	5.10	5.10	4
Nivolumab	Advanced Renal Cell Carcinoma 2nd line	5.4	5.50	0.98	5
Nivolumab	PDL1+ Metastatic gastro-esophageal junctional or gastric cancer Metastatic 1st line	3.3	6.80	0.49	2
Olaparib	BRCA mutant epithelial ovarian cancer maintenance treatment post 2nd line chemotherapy	16.3	29.10	0.56	4
Osimertinib	Metastatic EGFR mutant Non-small cell lung cancer 2nd line	10	13.80	0.72	4
Osimertinib	Metastatic EGFR mutant Non-small cell lung cancer 1st line	6.8	20.70	0.33	4
Pembrolizumab	Metastatic Melanoma	18.9	6.00	3.15	4
Pembrolizumab	Metastatic Non-small cell lung cancer PD1> 50% Single agent 1st Line treatment	15.8	7.90	2.00	5
Pembrolizumab	PDL1+ Metastatic Non-small cell lung cancer 2nd Line Single agent	4.2	3.50	1.20	5
Pembrolizumab	Metastatic Non-small cell lung cancer (Non-Squamous) 1st Line in combination with chemotherapy	11.3	9.80	1.15	4
Pembrolizumab	Metastatic Triple Negative Breast Cancer PDL1 > 10%	6.9	9.00	0.77	3
Pembrolizumab	Metastatic Oesophageal or Gastro-oesophageal Junctional Cancer PD1>10% 1st Line treatment in combination with chemotherapy	5.1	7.70	0.66	4
Pertuzumab	Metastatic HER2+ Breast Cancer first-line	15.7	16.80	0.93	4
Regorafenib	Treatment Refractory Metastatic Colorectal Cancer	1.4	2.80	0.50	1

Ribociclib	Metastatic Hormone Sensitive Breast Cancer 2nd Line	7.7	11.00	0.70	4
Ribociclib	Metastatic Hormone Sensitive Breast Cancer 1st Line	12.5	20.20	0.62	4
Ribociclib	Metastatic Pre-menopausalHormone Sensitive Breast Cancer 1st Line	10.7	24.00	0.45	5
Rituximab	Non-Hodgkin's Lymphoma 1st line	13	5.60	2.32	Not Assessed
Sorafenib	Advanced Hepatocellular carcinoma	2.8	5.30	0.53	Not Assessed
Sunitinib	Unresectable Gastrointestinal Stromal Tumour 2nd Line	8	3.00	2.67	3
Sunitinib	Advanced Renal Cell Carcinoma 1st Line	14	11.00	1.27	4
Trastuzumab	Metastatic HER2+ Breast Cancer first-line	14.6	9.75	1.50	Not Assessed
Trastuzumab	Metastatic HER2+ Gastric Adenocarcinoma first-line	2.7	5.60	0.48	3
trastuzumab deruxtecan	Metastatic Breast Cancer second-line	6.6	8.20	0.80	4
trastuzumab emtansine	Metastatic HER2+ Breast Cancer second-line	5.8	9.40	0.62	4

Supplementary Table 1

Overall survival gain per unit treatment time (Full Dataset)

Drug	Indication	Median Survival gain (In months)	Median Treatment Duration (In months)	Overall Survival gain per unit treatment time	ESMO-MCBS Score	Reference
Abiraterone	Metastatic Hormone Sensitive Prostate Cancer	16.8	25.80	0.65		Lancet Oncol. 2019;20(5):686-700
Abiraterone	Metastatic Castration Resistant Prostate Cancer Post Docetaxel	3.9	8.00	0.49		N Engl J Med. 2011;364(21): 1995- 2005
Abiraterone	Metastatic Castration Resistant Prostate Cancer Pre Docetaxel	4.4	13.77	0.32		Lancet Oncol. 2015 Feb;16(2):152-60.
Azacitadine	Acute Myeloid Leukaemia	5.2	8.80	0.59	Not Assessed	Blood. 2015. 126(3):291-299.
Bevacizumab	Platinum Refractory Epithelial Ovarian Cancer	3.3	4.20	0.79		J Clin Oncol. 2014;32(13):1302-8
Bevacizumab	Metastatic Cervical Cancer	3.7	4.90	0.76		N Engl J Med 2014; 370:734-743
Bevacizumab	Metastatic Colorectal Cancer 2nd line	2.1	4.67	0.45		J Clin Oncol. 2007;25(12):1539-44
Bevacizumab	Platinum Sensitive Relapsed Epithelial Ovarian Cancer	4.9	11.20	0.44		Lancet Oncol. 2017;18(6):779-791
Bevacizumab	Metastatic Non-squamous Non-small Cell Lung Cancer	2	4.90	0.41		N Engl J Med 2006; 355:2542-2550
Bevacizumab	Metastatic Epithelial Ovary Cancer 1st line	4.8	11.90	0.40		Lancet Oncol 2015; 16: 928–36
Bortezomib	Multiple Myeloma (Trasnplant Inlegible) VMP vs MP	13.3	12.00	1.11	Not Assessed	Blood. 2011;118(21):476


Cetuximab	Unresectable Squamous cell carcinoma of Head and Neck 1st Line treatment in combination with chemotherapy	2.7	4.20	0.64		3	N Engl J Med 2008; 359:1116-1127
Cetuximab	Metastatic RAS wildtype left sided colorectal cancer 1st line treatment in combination with chemotherapy	7	12.00	0.58		4	JAMA Oncol. 2017;3(2):194-20
Cetuximab	Treatment Refractory RAS wildtype Metastatic Colorectal Cancer (as monotherapy)	4.7	3.70	1.27		4	N Engl J Med 2008; 359:1757-1765
Dasatinib	Imatinib resistant Chronic Myeloid Leukaemia (in comparison to high dose imatinib)	15.72	78.00	0.20	Not Assessed		Value Health. 2011 Dec;14(8):1057-67
Decitabine	Acute Myeloid Leukaemia	2.7	4.40	0.61	Not Assessed		J Clin Oncol. 2012. 30(21):2670-7
Enzalutamide	Metastatic Castration Resistant Prostate Cancer Post Docetaxel	4.8	8.30	0.58		4	N Engl J Med 2012; 367:1187-1197
Enzalutamide	Metastatic Castration Resistant Prostate Cancer Pre Docetaxel	4	18.20	0.22		4	Eur Urol 2017;71(2):151-4
Fulvestrant	Metastatic Hormone Sensitive Breast Cancer 1st Line	7.8	15.00	0.52		2	N Engl J Med 2019; 380:1226-1234
Fulvestrant	Metastatic Hormone Sensitive Breast Cancer 2nd Line	4.1	6.50	0.63	Not Assessed		J Natl Cancer Inst. 2014 Jan;106(1):djt337
Lenalidomide	Multiple Myeloma (Trasnplant Inlegible) - Rd 18 Cycles	13.2	16.80	0.79	Not Assessed		Blood 2018 Jan 18;131(3):301-310
Lenvatinib	Radioiodine Refractory Metastatic Differentiated Thyroid Cancer	11.6	23.00	0.50		2	Eur J Cancer. 2021 Apr;147:51-57
Nab-Paclitaxel	Advanced Pancreatic Cancer	2.6	3.90	0.67		3	N Engl J Med 2013; 369:1691-1703
Nilotinib	Imatinib resistant Chronic Myeloid Leukaemia (in comparison to high dose imatinib)	9.12	29.28	0.31	Not Assessed		Value Health. 2011 Dec;14(8):1057-67
Nivolumab	Metastatic Melanoma	26	5.10	5.10		4	J Clin Oncol. 2020 Nov

						20;38(33):3937-3946
Nivolumab	Squamous cell carcinoma of the head and neck 2nd line	2.6	1.90	1.37	5	Oral Oncol . 2018 Jun;81:45-5
Nivolumab	Metastatic Non-small cell lung cancer 2nd line	3	3.00	1.00	5	J Clin Oncol. 2021 Mar 1;39(7):723-733
Nivolumab	Advanced Renal Cell Carcinoma 2nd line	5.4	5.50	0.98	5	N Engl J Med 2015; 373:1803-1813
Nivolumab	Metastatic Squamous Cell Carcinoma of Oesophagus 2nd line	2.5	2.60	0.96	3	Lancet Oncol. 2019 Nov;20(11):1506-1517.
Nivolumab	PDL1+ Metastatic gastro-esophageal junctional or gastric cancer Metastatic 1st line	3.3	6.80	0.49	2	Lancet 2021 Jul 3;398(10294):27-40
Olaparib	BRCA mutant epithelial ovarian cancer maintenance treatment post 2nd line chemotherapy	16.3	29.10	0.56	4	Lancet Oncol. 2021;22(5):620
Osimertinib	Metastatic EGFR mutant Non-small cell lung cancer 2nd line	10	13.80	0.72	4	Ann Oncol. 2020 Nov;31(11):1536-1544
Osimertinib	Metastatic EGFR mutant Non-small cell lung cancer 1st line	6.8	20.70	0.33	4	N Engl J Med 2020; 382:41-50
Panitumumab	Metastatic RAS wildtype colorectal cancer 1st line treatment in combination with chemotherapy	5.8	5.13	1.13	4	N Engl J Med 2013 Sep 12;369(11):1023-34.
Panitumumab	Treatment Refractory RAS wildtype Metastatic Colorectal Cancer (as monotherapy)	3.1	4.00	0.78	3	Br J Cancer. 2016;115:1206-1214
Pembrolizumab	Metastatic Melanoma	18.9	6.00	3.15	4	Lancet Oncol. 2019 Sep;20(9):1239-1251
Pembrolizumab	Metastatic Non-small cell lung cancer PD1> 50% Single agent 1st Line treatment	15.8	7.90	2.00	5	J Clin Oncol. 2019 Mar 1;37(7):537-546
Pembrolizumab	Unresectable PDL1+ Squamous cell carcinoma of head and neck 1st Line Single Agent Treatment	4.2	3.40	1.24	5	Lancet. 2019 Nov 23;394(10212):1915-1928

Pembrolizumab	PDL1+ Metastatic Non-small cell lung cancer 2nd Line Single agent	4.2	3.50	1.20		5	Lancet 2016; 387: 1540–50
Pembrolizumab	Metastatic Non-small cell lung cancer (Non-Squamous) 1st Line in combination with chemotherapy	11.3	9.80	1.15		4	J Clin Oncol 2020 May 10;38(14):1505-1517
Pembrolizumab	Metastatic Non-small cell lung cancer (Squamous) 1st Line in combination with chemotherapy	8	7.10	1.13		4	J Thoracic Oncol. 2020 Oct;15(10):1657-1669.
Pembrolizumab	Unresectable PDL1+ Squamous cell carcinoma of head and neck 1st Line treatment in combination with chemotherapy	5.9	5.80	1.02		4	Lancet. 2019 Nov 23;394(10212):1915-1928
Pembrolizumab	PD1+ Metastatic Cervical Cancer 1st line treatment in combination with chemotherapy	8	10.00	0.80		4	N Engl J Med 2021; 385:1856-1867
Pembrolizumab	Metastatic Triple Negative Breast Cancer PDL1 > 10%	6.9	9.00	0.77		3	N Engl J Med 2022; 387:217-226
Pembrolizumab	Metastatic Oesophageal or Gastro-oesophageal Junctional Cancer PD1>10% 1st Line treatment in combination with chemotherapy	5.1	7.70	0.66		4	Lancet 2021; 398: 759–71
Pembrolizumab	Metastatic Oesophageal or Gastro-oesophageal Junctional Cancer PD1>10% 2nd Line treatment single agent	2.6	4.00	0.65	Not Assessed		J Clin Oncol. 2020 Dec 10;38(35):4138-4148
Pertuzumab	Metastatic HER2+ Breast Cancer first-line	15.7	16.80	0.93		4	N Engl J Med 2015; 372:724-734
Pomalidamide	Multiple Myeloma 2nd line	7	4.67	1.50	Not Assessed		Br J Haematol. 2015 Mar;168(6):820-3.
Regorafenib	Treatment Refractory Metastatic Colorectal Cancer	1.4	2.80	0.50		1	Lancet.2013;381(9863):303
Ribociclib	Metastatic Hormone Sensitive Breast Cancer 2nd Line	7.7	11.00	0.70		4	N Engl J Med 2020; 382:514-524

Ribociclib	Metastatic Hormone Sensitive Breast Cancer 1st Line	12.5	20.20	0.62	4	N Engl J Med 2022; 386:942-950
Ribociclib	Metastatic Pre-menopausalHormone Sensitive Breast Cancer 1st Line	10.7	24.00	0.45	5	Clin Cancer Res. 2022 Mar 1;28(5):851-859
Rituximab	Non-Hodgkin's Lymphoma 1st line	13	5.60	2.32	Not Assessed	N Engl J Med 2002; 346:235-242 Blood. 2014; 124(21):1752 and J Natl Cancer Inst. 2007 May 2;99(9):706-14
Sorafenib	Advanced Hepatocellular carcinoma	2.8	5.30	0.53	Not Assessed	N Engl J Med 2008; 359:378-390
Sunitinib	Unresectable Gastrointestinal Stromal Tumour 2nd Line	8	3.00	2.67	3	Lancet. 2006;368(9544):1329, Clin Cancer Res. 2012 Jun 1; 18(11): 3170–3179.
Sunitinib	Advanced Renal Cell Carcinoma 1st Line	14	11.00	1.27	4	J Clin Oncol. 2009;27(22):3584-3590.
Trastuzumab	Metastatic HER2+ Breast Cancer first-line	14.6	9.75	1.50	Not Assessed	J Clin. Oncol. 2005 Jul 1;23(19):4265-74.
Trastuzumab	Metastatic HER2+ Gastric Adenocarcinoma first-line	2.7	5.60	0.48	3	Lancet 2010; 376: 687–97
trastuzumab deruxtecan	Metastatic Breast Cancer second-line	6.6	8.20	0.80	4	N Engl J Med 2022; 387:9-20
trastuzumab emtansine	Metastatic HER2+ Breast Cancer second-line	5.8	9.40	0.62	4	N Engl J Med 2012; 367:1783-1791

Number of Indications



Log (Survival gain per unit treatment time)

Activate Win
Go to Settings

